Skip to main content
BioCentury Innovations
< Next Issue 1 2 3 4 5 Prior Issue >
As published Thursday, June 25, 2015

By Karen Tkach, Staff Writer

Emulate Inc. is hoping its new partnership with Johnson & Johnson can get the biotech's Organs-on-Chips technology on the map for companies seeking to evaluate the safety and efficacy of their compounds. With three new industry partnerships for Emulate expected by year end, the company should be able to gather data to support its claim that the system can be widely deployed both to support drug development and understand mechanisms.

Last week, Emulate announced a deal with J&J's Janssen Biotech Inc. unit to use the technology to dissect mechanisms and improve predictions of adverse drug events in humans. Both sides are calling the deal a "long-term partnership" intended to last several years, with the first two projects focusing on lung thrombosis and liver toxicity.